Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ODC1 | P11926 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43474 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL203118 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL2639323 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL12775011 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL19107453 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL23765660 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL14745208 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL19107454 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL454356 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 | |
| SCHEMBL13079441 | 1.00 | MEN1 (0.38) | MEN1KMT2AODC1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114479-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | INSTITUTE OF PROCESS ENGINEERING , CHINESE ACADEMY OF SCIENCES (CN) | 2025-04-10 | — | — | US | claimed |
| CN-119775947-A | Adhesive, and preparation method and application thereof | 深圳市研一新材料有限责任公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119751856-A | Hyperbranched poly (beta-amino ester), preparation method thereof and application thereof in mRNA delivery | 首都医科大学附属北京朝阳医院 | 2025-04-04 | — | — | CN | claimed |
| CN-119708521-A | Preparation method and application of lung organ targeted branched poly (beta-amino ester) based mRNA (messenger ribonucleic acid) compound nano particles | 复旦大学附属儿科医院 | 2025-03-28 | — | — | CN | claimed |
| CN-119552130-A | Compound containing bisisatoic anhydride functional group, polymer with pH and temperature dual stimulus response, preparation method and application thereof | 广州工程技术职业学院 | 2025-03-04 | — | — | CN | claimed |
| CN-119431775-A | Branched fluorine-containing poly (beta-amino ester) and preparation method and application thereof | 北京大学 | 2025-02-14 | — | — | CN | claimed |
| WO-2025034923-A1 | METHODS AND COMPOSITIONS FOR THE PROUDCTION OF AMIDES FROM SUGAR LACTONES | SOLUGEN, INC. (US) | 2025-02-13 | — | — | WO | claimed |
| CN-119409987-A | Hyperbranched poly (beta-amino ester), preparation method, composite nanoparticle and application | 复旦大学附属儿科医院 | 2025-02-11 | — | — | CN | claimed |
| CN-119391164-A | Polyurethane resin with ultra-soft high hydrolysis resistance and preparation method thereof | 浙江禾欣科技有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-119242251-A | Intrinsic flame-retardant waterborne polyurethane adhesive and preparation method and application thereof | 淮安凯悦科技开发有限公司 | 2025-01-03 | — | — | CN | claimed |
| EP-3246037-A1 | CROSSLINKED CHONDROITIN SULFATE, COMPOSITION CONTAINING SAME, AND TREATMENT AGENT FOR EYE DISEASE | Seikagaku Corporation (JP) | 2017-11-22 | — | — | EP | claimed |
| US-20170202971-A1 | Oxazoline Polymer Compositions and Use Thereof | ANP TECH INC (US) | 2017-07-20 | — | — | US | claimed |
| US-20170066879-A1 | Oxazoline Polymer Compositions and Use Thereof | FULGENT GENETICS, INC. | 2017-03-09 | — | — | US | claimed |
| EP-3116935-A1 | NOVEL COVALENTLY CROSS-LINKED MALLEABLE POLYMERS AND METHODS OF USE | The Regents of the University of Colorado, a body corporate (US) | 2017-01-18 | — | — | EP | claimed |
| WO-2016179017-A1 | USE OF ACTIVE AGENTS DURING CHEMICAL TREATMENTS | L'OREAL (FR) | 2016-11-10 | — | — | WO | claimed |
| US-20160024252-A1 | Oxazoline Polymer Compositions and Use Thereof | ANP TECHNOLOGIES, INC. (US) | 2016-01-28 | — | — | US | claimed |
| US-20150344613-A1 | POLYTHIOUREA COMPOSITIONS AND METHODS OF USE | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-12-03 | — | — | US | claimed |
| WO-2015138804-A1 | NOVEL COVALENTLY CROSS-LINKED MALLEABLE POLYMERS AND METHODS OF USE | THE REGENTS OF THE UNIVERITY OF COLORADO, A BODY CORPORATE (US) | 2015-09-17 | — | — | WO | claimed |
| CN-104232077-A | Monopyrene fluorescent probe based on cholesterol modification, and synthesis method and application thereof | UNIV SHAANXI NORMAL | 2014-12-24 | — | — | CN | claimed |
| WO-2013020005-A2 | OXAZOLINE POLYMER COMPOSITIONS AND USE THEREOF | ANP TECHNOLOGIES, INC. (US) | 2013-02-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114479-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | SLC43A1, LNPEP, TLR3 | MEN1 4368/4885KMT2A 2917/4885ODC1 1945/4885 |
| US-20150344613-A1 | POLYTHIOUREA COMPOSITIONS AND METHODS OF USE | PNMT, SRM, PUF60 | MEN1 1271/4885KMT2A 50/4885ODC1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.